EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

The role of the endocannabinoid system in managing neuropsychiatric symptoms in Alzheimer’s disease

Jagadeesh S Rao, Maria Alejandra Tangarife, Maria Margarita Venegas, Barbara Forero, Laura Lucía González Tamayo, Juan Pablo Escobar-Gallego, Diego A Rodríguez-Soacha, Alexandra Ferreiros, Ram Mukunda

Frontiers in Psychiatry · 13.01.2026 · 16

DOI: 10.3389/fpsyt.2025.1709266 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Frontiers in Psychiatry, online erschienen am 13.01.2026. Verfasst von Jagadeesh S Rao und 8 weiteren Autor:innen. Beteiligte Einrichtung: IGC Pharma Inc., Potomac, MD, United States. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 183 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The endocannabinoid system comprises cannabinoid receptors (CBRs) 1 & 2, endocannabinoids (eCBs) anandamide (AEA) and 2-arachidonoylglycerol (2-AG), and the enzymes that regulate their production and degradation. ECS plays a significant role in both health and disease. It influences neuronal and glial communications, neurotransmitter regulations, neuroinflammation, and behavioral alterations. Neuropsychiatric symptoms (NPS) are commonly seen in neurodegenerative conditions like Alzheimer’s disease (AD), apart from the core clinical diagnosis of dementia. NPS consists of various disturbing symptoms, including anxiety, agitation, apathy, hallucinations, delusions, sleeping problems, appetite problems, and depression. In AD, up to 97% exhibit one or more NPS. Emerging evidence from preclinical and clinical studies suggests that ECS is both a contributor to and a potential therapeutic target for managing NPS. This review explores ECS’s role in NPS and its therapeutic implications.

Schlagwörter

Stichwörter der Autor:innen

Alzheimer’s diseaseagitationanxietyapathyappetitedelusionsdepressionhallucinations

Autor:innen und Institutionen

  • IGC Pharma Inc., Potomac, MD, United States.

Zitieren

APA

Rao, J. S., Alejandra Tangarife, M., Venegas, M. M., Forero, B., González Tamayo, L. L., Escobar-Gallego, J. P., Rodríguez-Soacha, D. A., Ferreiros, A., & Mukunda, R. (2026). The role of the endocannabinoid system in managing neuropsychiatric symptoms in Alzheimer’s disease. Frontiers in Psychiatry, 16. https://doi.org/10.3389/fpsyt.2025.1709266

Vancouver

Rao JS, Alejandra Tangarife M, Venegas MM, Forero B, González Tamayo LL, Escobar-Gallego JP, et al. The role of the endocannabinoid system in managing neuropsychiatric symptoms in Alzheimer’s disease. Frontiers in Psychiatry. 2026;16. doi:10.3389/fpsyt.2025.1709266

BibTeX
@article{Rao2026,
  author = {Rao, Jagadeesh S and Alejandra Tangarife, Maria and Venegas, Maria Margarita and Forero, Barbara and González Tamayo, Laura Lucía and Escobar-Gallego, Juan Pablo and Rodríguez-Soacha, Diego A and Ferreiros, Alexandra and Mukunda, Ram},
  title = {The role of the endocannabinoid system in managing neuropsychiatric symptoms in Alzheimer’s disease},
  journal = {Frontiers in Psychiatry},
  year = {2026},
  volume = {16},
  doi = {10.3389/fpsyt.2025.1709266}
}
Kostenlos starten →